Patents by Inventor Joachim Schuhmacher
Joachim Schuhmacher has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240108766Abstract: The present invention relates to conjugates comprising a chelator arranged for complexation of a radionuclide and a targeting moiety binding to LRRC15. For example, the conjugates according to the current invention can be targeted alpha therapeutics such as targeted thorium conjugates (TTCs), i.e. radioconjugates comprising an alpha emitter, such as 227Th. The present invention further relates to sequence-defined antibodies binding LRRC15 and antigen-binding fragments thereof. Also provided are conjugates comprising these antibodies or functional fragments thereof. The antibodies, functional fragments and conjugates according to the current invention can be used to treat cancer and other disorders and conditions associated with the expression of LRRC15.Type: ApplicationFiled: January 17, 2022Publication date: April 4, 2024Inventors: Mark TRAUTWEIN, Urs Beat HAGEMANN, Phillipp ELLINGER, Stephan MAERSCH, Joachim SCHUHMACHER, Antje WENGNER, Roger Malerbakken BJERKE, Helge ROIDER
-
Publication number: 20200377614Abstract: The present invention provides immunoconjugates composed of antibodies, e.g., monoclonal antibodies, or antibody fragments that bind to mesothelin, that are conjugated to cytotoxic agents, e.g., maytansine, or derivatives thereof, and/or co-administered or formulated with one or more additional anti-cancer agents. The immunoconjugates of the invention can be used in the methods of the invention to treat and/or diagnose and/or monitor cancers, e.g. solid tumors.Type: ApplicationFiled: August 17, 2020Publication date: December 3, 2020Applicant: Bayer Intellectual Property GmbHInventors: Antje KAHNERT, Kerstin UNTERSCHEMMANN, Iring HEISLER, Charlotte Christine KOPITZ, Joachim SCHUHMACHER
-
Patent number: 10781263Abstract: The present invention provides immunoconjugates composed of antibodies, e.g., monoclonal antibodies, or antibody fragments that bind to mesothelin, that are conjugated to cytotoxic agents, e.g., maytansine, or derivatives thereof, and/or co-administered or formulated with one or more additional anti-cancer agents. The immunoconjugates of the invention can be used in the methods of the invention to treat and/or diagnose and/or monitor cancers, e.g. solid tumors, recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for the membrane-anchored, 40 kDa mesothelin polypeptide, which is overexpressed in several tumors, such as pancreatic and ovarian tumors, mesothelioma and lung cancer cells.Type: GrantFiled: March 16, 2018Date of Patent: September 22, 2020Assignee: Bayer Intellectual Property GmbHInventors: Antje Kahnert, Kerstin Unterschemmann, Iring Heisler, Charlotte Christine Kopitz, Joachim Schuhmacher
-
Patent number: 10668071Abstract: The present application relates to novel substituted (aza)pyridopyrazolopyrimidinones and indazolopyrimidinones, to processes for their preparation, the compounds for use alone or in combinations in a method for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of acute and recurrent bleeding in patients with or without underlying hereditary or acquired bleeding disorders, wherein the bleeding is associated with a disease or medical intervention selected from the group consisting of menorrhagia, postpartum hemorrhage, hemorrhagic shock, trauma, surgery, transplantation, stroke, liver diseases, hereditary angioedema, nosebleed, and synovitis and cartilage damage following hemarthrosis.Type: GrantFiled: August 10, 2018Date of Patent: June 2, 2020Assignee: BAYER PHARMA AKTIENGESELLSCHAFTInventors: Jorma Haßfeld, Tom Kinzel, Johannes Köbberling, Yolanda Cancho-Grande, Kristin Beyer, Susanne Röhrig, Maria Köllnberger, Michael Sperzel, Nils Burkhardt, Karl-Heinz Schlemmer, Christian Stegmann, Joachim Schuhmacher, Matthias Werner, Manuel Ellermann
-
Patent number: 10647779Abstract: The present invention provides immunoconjugates composed of antibodies, e.g., monoclonal antibodies, or antibody fragments that bind to mesothelin, that are conjugated to cytotoxic agents, e.g., maytansine, or derivatives thereof, and/or co-administered or formulated with one or more additional anti-cancer agents. The immunoconjugates of the invention can be used in the methods of the invention to treat and/or diagnose and/or monitor cancers, solid tumors, recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for the membrane-anchored, 40 kDa mesothelin polypeptide, which which is overexpressed in several tumors, such as pancreatic and ovarian tumors, mesothelioma and lung cancer cells.Type: GrantFiled: July 21, 2017Date of Patent: May 12, 2020Assignee: Bayer Intellectual Property GmbHInventors: Antje Kahnert, Kerstin Unterschemmann, Iring Heisler, Charlotte Kopitz, Joachim Schuhmacher
-
Publication number: 20180344739Abstract: The present application relates to novel substituted (aza)pyridopyrazolopyrimidinones and indazolopyrimidinones, to processes for their preparation, the compounds for use alone or in combinations in a method for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of acute and recurrent bleeding in patients with or without underlying hereditary or acquired bleeding disorders, wherein the bleeding is associated with a disease or medical intervention selected from the group consisting of menorrhagia, postpartum hemorrhage, hemorrhagic shock, trauma, surgery, transplantation, stroke, liver diseases, hereditary angioedema, nosebleed, and synovitis and cartilage damage following hemarthrosis.Type: ApplicationFiled: August 10, 2018Publication date: December 6, 2018Inventors: Jorma HAßFELD, Tom KINZEL, Johannes KÖBBERLING, Yolanda CANCHO-GRANDE, Kristin BEYER, Susanne RÖHRIG, Maria KÖLLNBERGER, Michael SPERZEL, Nils BURKHARDT, Karl-Heinz SCHLEMMER, Christian STEGMANN, Joachim SCHUHMACHER, Matthias WERNER, Manuel ELLERMANN
-
Patent number: 10118930Abstract: The present application relates to novel substituted piperidinylpyrazolopyrimidinones, to processes for their preparation, the compounds for use alone or in combinations in a method for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of acute and recurrent bleeding in patients with or without underlying hereditary or acquired hemostatic disorders, wherein the bleeding is associated with a disease or medical intervention selected from the group consisting of heavy menstrual bleeding, postpartum hemorrhage, hemorrhagic shock, hemorrhagic cystitis, gastrointestinal hemorrhage, trauma, surgery, transplantation, stroke, liver diseases, hereditary angioedema, nosebleed, and synovitis and cartilage damage following hemarthrosis.Type: GrantFiled: October 30, 2015Date of Patent: November 6, 2018Assignee: BAYER PHARMA AKTIENGESELLSCHAFTInventors: Manuel Ellermann, Gaelle Valot, Yolanda Cancho Grande, Jorma Haßfeld, Tom Kinzel, Johannes Köbberling, Kristin Beyer, Susanne Röhrig, Michael Sperzel, Jan Stampfuß, Imke Meyer, Maria Köllnberger, Nils Burkhardt, Karl-Heinz Schlemmer, Christian Stegmann, Joachim Schuhmacher, Matthias Werner, Jörg Heiermann, Willem Jan Hengeveld
-
Patent number: 10098883Abstract: The present application relates to novel substituted (aza)pyridopyrazolopyrimidinones and indazolopyrimidinones, to processes for their preparation, the compounds for use alone or in combinations in a method for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of acute and recurrent bleeding in patients with or without underlying hereditary or acquired bleeding disorders, wherein the bleeding is associated with a disease or medical intervention selected from the group consisting of menorrhagia, postpartum hemorrhage, hemorrhagic shock, trauma, surgery, transplantation, stroke, liver diseases, hereditary angioedema, nosebleed, and synovitis and cartilage damage following hemarthrosis.Type: GrantFiled: January 26, 2017Date of Patent: October 16, 2018Assignee: BAYER PHARMA AKTIENGESELLSCHAFTInventors: Jorma Haßfeld, Tom Kinzel, Johannes Köbberling, Yolanda Cancho-Grande, Kristin Beyer, Susanne Röhrig, Maria Köllnberger, Michael Sperzel, Nils Burkhardt, Karl-Heinz Schlemmer, Christian Stegmann, Joachim Schuhmacher, Matthias Werner, Manuel Ellermann
-
Publication number: 20180201690Abstract: The present invention provides immunoconjugates composed of antibodies, e.g., monoclonal antibodies, or antibody fragments that bind to mesothelin, that are conjugated to cytotoxic agents, e.g., maytansine, or derivatives thereof, and/or co-administered or formulated with one or more additional anti-cancer agents. The immunoconjugates of the invention can be used in the methods of the invention to treat and/or diagnose and/or monitor cancers, e.g. solid tumors, recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for the membrane-anchored, 40 kDa mesothelin polypeptide, which which is overexpressed in several tumors, such as pancreatic and ovarian tumors, mesothelioma and lung cancer cells.Type: ApplicationFiled: March 16, 2018Publication date: July 19, 2018Applicant: Bayer Intellectual Property GmbHInventors: Antje Kahnert, Kerstin Unterschemmann, Iring Heisler, Charlotte Christine Kopitz, Joachim Schuhmacher
-
Publication number: 20170334917Abstract: The present application relates to novel substituted piperidinylpyrazolopyrimidinones, to processes for their preparation, the compounds for use alone or in combinations in a method for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of acute and recurrent bleeding in patients with or without underlying hereditary or acquired hemostatic disorders, wherein the bleeding is associated with a disease or medical intervention selected from the group consisting of heavy menstrual bleeding, postpartum hemorrhage, hemorrhagic shock, hemorrhagic cystitis, gastrointestinal hemorrhage, trauma, surgery, transplantation, stroke, liver diseases, hereditary angioedema, nosebleed, and synovitis and cartilage damage following hemarthrosis.Type: ApplicationFiled: October 30, 2015Publication date: November 23, 2017Applicant: BAYER PHARMA AKTIENGESELLSCHAFTInventors: Manuel ELLERMANN, Gaelle VALOT, Yolanda CANCHO GRANDE, Jorma HAßFELD, Tom KINZEL, Johannes KÖBBERLING, Kristin BEYER, Susanne RÖHRIG, Michael SPERZEL, Jan STAMPFUß, Imke MEYER, Maria KÖLLNBERGER, Nils BURKHARDT, Karl-Heinz SCHLEMMER, Christian STEGMANN, Joachim SCHUHMACHER, Matthias WERNER, Jörg HEIERMANN, Willem Jan HENGEVELD
-
Publication number: 20170239251Abstract: The present application relates to novel substituted (aza)pyridopyrazolopyrimidinones and indazolopyrimidinones, to processes for their preparation, the compounds for use alone or in combinations in a method for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of acute and recurrent bleeding in patients with or without underlying hereditary or acquired bleeding disorders, wherein the bleeding is associated with a disease or medical intervention selected from the group consisting of menorrhagia, postpartum hemorrhage, hemorrhagic shock, trauma, surgery, transplantation, stroke, liver diseases, hereditary angioedema, nosebleed, and synovitis and cartilage damage following hemarthrosis.Type: ApplicationFiled: January 26, 2017Publication date: August 24, 2017Inventors: Jorma HAßFELD, Tom KINZEL, Johannes KÖBBERLING, Yolanda CANCHO-GRANDE, Kristin BEYER, Susanne RÖHRIG, Maria KÖLLNBERGER, Michael SPERZEL, Nils BURKHARDT, Karl-Heinz SCHLEMMER, Christian STEGMANN, Joachim SCHUHMACHER, Matthias WERNER, Manuel ELLERMANN
-
Patent number: 9598417Abstract: The present application relates to novel substituted (aza)pyridopyrazolopyrimidinones and indazolopyrimidinones, to processes for their preparation, the compounds for use alone or in combinations in a method for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of acute and recurrent bleeding in patients with or without underlying hereditary or acquired bleeding disorders, wherein the bleeding is associated with a disease or medical intervention selected from the group consisting of menorrhagia, postpartum hemorrhage, hemorrhagic shock, trauma, surgery, transplantation, stroke, liver diseases, hereditary angioedema, nosebleed, and synovitis and cartilage damage following hemarthrosis.Type: GrantFiled: November 5, 2014Date of Patent: March 21, 2017Assignee: BAYER PHARMA AKTIENGESELLSCHAFTInventors: Jorma Haβfeld, Tom Kinzel, Johannes Köbberling, Yolanda Cancho Grande, Kristin Beyer, Susanne Röhrig, Maria Köllnberger, Michael Sperzel, Nils Burkhardt, Karl-Heinz Schlemmer, Christian Stegmann, Joachim Schuhmacher, Matthias Werner, Manuel Ellermann
-
Publication number: 20160229858Abstract: The present application relates to novel substituted dihydropyrazolone derivatives, processes for their preparation, their use for treatment and/or prophylaxis of diseases and their use for the preparation of medicaments for treatment and/or prophylaxis of diseases, in particular cardiovascular and hematological diseases and kidney diseases, and for promoting wound healing.Type: ApplicationFiled: September 25, 2015Publication date: August 11, 2016Inventors: Kai THEDE, Ingo FLAMME, Felix OEHME, Jens-Kerim ERGÜDEN, Friederike STOLL, Joachim SCHUHMACHER, Hanno WILD, Peter KOLKHOF, Hartmut BECK, Jörg KELDENICH, Metin AKBABA, Mario JESKE
-
Publication number: 20160193359Abstract: The present application relates to new binder-drug conjugates (ADCs) of N,N-dialkylauristatins that are directed against the target C4.4a, to active metabolites of these ADCs, to processes for preparing these ADCs, to the use of these ADCs for treating and/or preventing illnesses, and also to the use of these ADCs for producing medicaments for treating and/or preventing illnesses, more particularly hyperproliferative and/or angiogenic diseases such as, for example, cancer diseases. Such treatments may be practised as a monotherapy or else in combination with other medicaments or further therapeutic measures.Type: ApplicationFiled: February 24, 2016Publication date: July 7, 2016Applicant: SEATTLE GENETICS, INC.Inventors: Hans-Georg LERCHEN, Lars LINDEN, Sherif EL SHEIKH, Jörg WILLUDA, Charlotte C. KOPITZ, Joachim SCHUHMACHER, Simone GREVEN, Christoph MAHLERT, Beatrix STELTE-LUDWIG, Sven GOLFIER, Rudolf BEIER, Iring HEISLER, Axel HARRENGA, Karl-Heinz THIERAUCH, Sandra BRUDER, Heike PETRUL, Hannah Jörißen, Sandra BORKOWSKI
-
Patent number: 9168249Abstract: The present application relates to novel substituted dihydropyrazolone derivatives, processes for their preparation, their use for treatment and/or prophylaxis of diseases and their use for the preparation of medicaments for treatment and/or prophylaxis of diseases, in particular cardiovascular and hematological diseases and kidney diseases, and for promoting wound healing.Type: GrantFiled: February 4, 2015Date of Patent: October 27, 2015Assignee: Bayer Intellectual Property GmbHInventors: Kai Thede, Ingo Flamme, Felix Oehme, Jens-Kerim Ergüden, Friederike Stoll, Joachim Schuhmacher, Hanno Wild, Peter Kolkhof, Hartmut Beck, Jörg Keldenich, Metin Akbaba, Mario Jeske
-
Publication number: 20150246136Abstract: The present patent application relates to novel binder-drug conjugates (ADCs) of N,N-dialkylauristatins directed against the target epidermal growth factor receptor (EGFR, gene ID 1956), effective metabolites of these ADCs, methods for producing these ADCs, use of these ADCs for treatment and or prevention of diseases as well as the use of these ADCs to produce pharmaceutical drugs for treatment and/or prevention of diseases, in particular hyperproliferative and/or angiogenic diseases such as cancer, for example. Such treatments may be administered as monotherapy or in combination with other pharmaceutical drugs or other therapeutic measures.Type: ApplicationFiled: May 11, 2015Publication date: September 3, 2015Applicant: SEATTLE GENETICS, INC.Inventors: Hans-Georg LERCHEN, Lars LINDEN, Sherif El SHEIKH, Jörg WILLUDA, Charlotte C. KOPITZ, Joachim SCHUHMACHER, Simone GREVEN, Christoph MAHLERT, Beatrix STELTE-LUDWIG, Sven GOLFIER, Rudolf BEIER, Iring HEISLER, Axel HARRENGA, Karl-Heinz THIERAUCH, Sandra BRUDER, Heike PETRUL, Hannah JÖRISSEN, Sandra BORKOWSKI
-
Patent number: 9085572Abstract: The present application relates to novel dipyridyl-dihydropyrazolones, processes for their preparation, their use for treatment and/or prophylaxis of diseases and their use for the preparation of medicaments for treatment and/or prophylaxis of diseases, in particular cardiovascular and hematological diseases and kidney diseases, and for promoting wound healing.Type: GrantFiled: August 24, 2012Date of Patent: July 21, 2015Assignee: Bayer Intellectual Property GmbHInventors: Ingo Flamme, Jens-Kerim Ergüden, Felix Oehme, Kai Thede, Gunter Karig, Alexander Kuhl, Hanno Wild, Joachim Schuhmacher, Peter Kolkhof, Lars Bärfacker, Joachim Hütter
-
Patent number: 9084829Abstract: The present invention provides immunoconjugates composed of antibodies, e.g., monoclonal antibodies, or antibody fragments that bind to mesothelin, that are conjugated to cytotoxic agents, e.g., maytansine, or derivatives thereof, and/or co-administered or formulated with one or more additional anti-cancer agents. The immunoconjugates of the invention can be used in the methods of the invention to treat and/or diagnose and/or monitor cancers, e.g. solid tumors. The immunoconjugates comprise antibodies and functional fragments containing such antigen-binding regions that are specific for the membrane-anchored, 40 kDa mesothelin polypeptide, which is overexpressed in several tumors, such as pancreatic and ovarian tumors, mesothelioma and lung cancer cells.Type: GrantFiled: April 16, 2010Date of Patent: July 21, 2015Assignee: Bayer Intellectual Property GmbHInventors: Antje Kahnert, Kerstin Berhörster, Iring Heisler, Charlotte Christine Kopitz, Joachim Schuhmacher
-
Publication number: 20150148381Abstract: The present application relates to novel substituted dihydropyrazolone derivatives, processes for their preparation, their use for treatment and/or prophylaxis of diseases and their use for the preparation of medicaments for treatment and/or prophylaxis of diseases, in particular cardiovascular and hematological diseases and kidney diseases, and for promoting wound healing.Type: ApplicationFiled: February 4, 2015Publication date: May 28, 2015Inventors: Kai THEDE, Ingo FLAMME, Felix OEHME, Jens-Kerim ERGÜDEN, Friederike STOLL, Joachim SCHUHMACHER, Hanno WILD, Peter KOLKHOF, Hartmut BECK, Jörg KELDENICH, Metin AKBABA, Mario JESKE
-
Publication number: 20150148298Abstract: The present application relates to new derivatives of monomethylauristatin F, substituted on the N terminus by a carboxyalkyl group, processes for preparing these derivatives, their use for the treatment and/or prevention of diseases and to produce medication for the treatment and/or prevention of diseases, particularly hyperproliferative and/or angiogenic disorders such as cancer disorders, for example. Such treatments can occur as monotherapies or in combination with other medication or further therapeutic measures.Type: ApplicationFiled: February 5, 2015Publication date: May 28, 2015Applicant: SEATTLE GENETICS, INC.Inventors: Hans-Georg LERCHEN, Sherif El Sheikh, Beatrix Stelet-Ludwig, Sven Golfier, Joachim Schuhmacher, Jean Mark Gnoth, Ursula Krenz